BD INSYTE™ AUTOGUARD™ BC
Transcription
BD INSYTE AUTOGUARD BC ™ ™ with blood control technology All the familiar sizes of BD Insyte Autoguard, now with Blood Control Technology BD Insyte™ Autoguard™ BC Product Information Non-Winged Winged 382512 382612 382523 Gauge Length Flow Rate Catheter OD Catheter ID Units Box/Case 24 0.75 in. (0.7 mm x 19 mm) 20 mL/min .026 in.-.029 in. (0.66-0.74 mm) .019 in.-.022 in. (0.48-0.56 mm) 50/200 382623 22 1.00 in. (0.9 mm x 25 mm) 37 mL/min .033 in.-.036 in. (0.84-0.91 mm) .024 in.-.027 in. (0.61-0.69 mm) 50/200 382533 382633 20 1.00 in. (1.1 mm x 25 mm) 63 mL/min .041 in.-.044 in. (1.04-1.12 mm) .030 in.-.033 in. (0.76-0.84 mm) 50/200 382534 382634 20 1.16 in. (1.1 mm x 30 mm) 61 mL/min .041 in.-.044 in. (1.04-1.12 mm) .030 in.-.033 in. (0.76-0.84 mm) 50/200 382537 382637 20 1.88 in. (1.1 mm x 48 mm) 54 mL/min .041 in.-.044 in. (1.04-1.12 mm) .030 in.-.033 in. (0.76-0.84 mm) 50/200 382544 382644 18 1.16 in. (1.3 mm x 30 mm) 95 mL/min .050 in.-.053 in. (1.27-1.35 mm) .037 in.-.040 in. (0.94-1.02 mm) 50/200 382547 382647 18 1.88 in. (1.3 mm x 48 mm) 87 mL/min .050 in.-.053 in. (1.27-1.35 mm) .037 in.-.040 in. (0.94-1.02 mm) 50/200 382554 382654 16 1.16 in. (1.7 mm x 30 mm) 193 mL/min .067 in.-.070 in. (1.70-1.78 mm) .052 in.-.055 in. (1.32-1.40 mm) 50/200 382557 382657 16 1.77 in. (1.7 mm x 45 mm) 185 mL/min .067 in.-.070 in. (1.70-1.78 mm) .052 in.-.055 in. (1.32-1.40 mm) 50/200 Making safety safer The 18 to 22 gauge catheters are capable of withstanding high-pressure injection procedures. To order or learn more about BD Insyte™ Autoguard™ BC, call 1.888.237.2762 or visit www.bd.com/IAGBC 1Onia R, Eshun-Wilson I, Arce C, et al. Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure. Curr Med Res Opin. 2011;27(7):1339-1346. * comparison to a traditional peripheral IV catheter 2 Jagger J, Perry J, Parker G, et al. Blood exposure risk during peripheral I.V. catheter insertion and removal. Nursing. 2011;41(12):45-49. 3 Richardson D, Kaufman L. Reducing blood exposure risks and costs associated with SPIVC insertion. Nurs Manage. 2011;42(12):31-34. 4Mendelson MH, Lin-Chen BY, Finkelstein-Blond L, Bailey E, Kogan G. Evaluation of a safety IV catheter (IVC) (Becton Dickinson, Insyte Autoguard): final report [abstract]. Eleventh Annual Scientific Meeting Society for Healthcare Epidemiology of America. 2001. ** comparison to a non-safety peripheral IV catheter 5Gaukroger PB, Roberts JG, Manners TA. Infusion thrombophlebitis: a prospective comparison of 645 Vialon and Teflon cannulae in anaesthetic and postoperative use. Anaesthesia and Intensive Care. 1988;16:265-271. 6Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. Annals of Internal Medicine. 1991;114:845-854. BD, BD Logo, and all other trademarks are property of Becton, Dickinson and Company. © 2013 BD. Printed in the USA BD Medical 9450 South State Street Sandy, Utah 84070 1.888.237.2762 www.bd.com/IAGBC MSS0258-1B (1/13) SM BD Insyte™ Autoguard™ BC: clinically shown to reduce the risk of blood exposure by 95% * Making safety safer for you Standard non-blood-control IV catheter 1 The healthcare industry has come a long way in preventing needlestick injuries and their potential dangers. Even so, blood exposure during a peripheral IV insertion is still a factor—and a risk—to healthcare workers and patients. Reduce Cross-Contamination Risks Because there is dramatically less blood leakage at insertion, BD Insyte™ Autoguard™ BC can mean less potential cross contamination. Minimizing spills means there’s less blood to get on gloves, clothing, shoes, bedding, floors, or equipment.1 Study Data • A study shows the rate of at-risk blood exposure for IV catheter insertions is 128 per 100,000 insertions (this is the combined rate of blood contact to the eyes, nose, mouth, and nonintact skin).2 • A study shows that while placing a peripheral IV catheter, clinicians often use gauze, absorbent drape, towels or sheets.3 • A study shows the average cost per cleanup for these materials is $0.30 per insertion.3 BD Blood Control Technology—designed to stop blood so it doesn’t escape the hub. Controlling blood escape means a cleaner area helping to increase patient confidence. Clinically Demonstrated Now blood exposure doesn’t have to be “part of the job.” In a clinical study, 98% of clinicians stated they had no risk of blood exposure during insertion when using BD Insyte Autoguard BC,1* which means: NEW • New blood-control technology shown to reduce the risk of blood exposure by 95%.1* BD Blood Control Technology • Push-button shielding technology proven to reduce needlestick injuries by 95%.4** • BD Vialon™ biomaterial—is designed to soften in the vein and provides greater kink resistance5 and longer dwell time6 compared to FEP polymer. • Less risk of exposure to bloodborne pathogens. • Virtually no clean up of blood spills. • No need to worry about stopping blood.1 BD Instaflash™ Needle Technology Push-button Needle Shielding Safety Beyond Needlestick Protection • Virtually no blood leakage and immediate cost savings on clean-up supplies. BD Insyte™ Autoguard™ BC IV catheters are a part of the BD Medical family of products—products that reflect a continuing commitment to keeping healthcare workers safer worldwide. To order or request more information, call 1.888.237.2762 or visit www.bd.com/IAGBC “Because one blood droplet found my eye, I was at risk.” c h ery l l co l l ins , bsn , rn , ocn View Cheryll’s and other blood exposure stories online at www.bd.com/ bloodcontrol BD Vialon™ Biomaterial Complete Needle Encapsulation
Similar documents
Closed IV Catheter - B. Braun Medical Inc.
• Cut costs by reducing needlesticks and cleanup time and materials.
More informationGlobal Market Study on Peripheral Intravenous Catheter Market, 2015-2021
The global peripheral intravenous catheter market was valued at US$ 3,500 Mn in 2014. North America was the largest market for peripheral intravenous catheters, accounting for over 45% revenue share of the overall market in 2014, followed by Europe with around 27% share. Moreover, Asia-Pacific market is expected to exhibit highest CAGR of 6.7% during the forecast period (2015–2021), followed by the North America. Factors such as increasing per capita healthcare spending, increasing aging population, increase in a number of diseases, and advancement in PIVC technology are expected to support a growth of the peripheral intravenous catheter market over the forecast period.
More informationPeripheral I.V. Catheter Market Analysis and Demand Forecast to 2022
The global peripheral I.V. catheter market was valued at $3,702.2 million in 2015, and it is expected to grow at a CAGR of 6.0% during the period 2016 - 2022. The global market is increasing, due to growing geriatric population and increasing incidence of chronic diseases. In addition, the growing demand for injectable drugs in comparison to the oral medications, increasing healthcare expenditure and technological advancements in peripheral I.V. catheter is encouraging the growth of the global peripheral I.V. catheter market.
More information